$JBIO

Jade Biosciences, Inc.

Jade Biosciences is a clinical-stage biopharmaceutical company developing biologic therapies for patients with autoimmune diseases. It is based in Waltham, Massachusetts. Jade’s lead product candidate, JADE101, is a monoclonal antibody targeting APRIL for the treatment of IgA nephropathy. Jade initiated a Phase 1 clinical trial of JADE101 in healthy volunteers in New Zealand in August 2025. Its second candidate, JADE201, is an antibody targeting the BAFF receptor for the treatment of multiple autoimmune disorders. Jade also has an exclusive option to license JADE301, an antibody program targeting an undisclosed pathway. Paragon Therapeutics conducts preclinical discovery services for JADE301, including generating and testing potential antibody candidates.

2
0
4

No SEC Form 4 filings for $JBIO in the last 30 days.

See all $JBIO insider activity →
Med

Guggenheim cuts Jade Biosciences stock price target on model changes

Guggenheim reduced its price target for Jade Biosciences (JBIO) to $41 from $47, citing model adjustments. The stock trades at $16.14, below the analyst consensus range of $40-$77. The company expects to start a Phase 3 trial for JADE101 this quarter and report interim Phase 2 data in 2027. Other analysts maintain Buy ratings with higher targets, highlighting the company's clinical progress and financial health.

Jade Biosciences stock maintained at Buy by BTIG, $77 target

BTIG maintained a Buy rating and $77 target for Jade Biosciences (JBIO), citing strong gains and potential in IgAN market. The company has $476M in cash, with trials expected to deliver data in 2027. Multiple analysts reiterated positive ratings, highlighting JADE301's potential.

Jade Biosciences 3Q 2026: EPS ($0.42) — 10-Q Summary

Jade Biosciences reported a wider net loss of $35.06M in Q3 2026, with no revenue and higher operating expenses. Diluted EPS was ($0.42). The company has $475.7M in cash and expects it to last 12 months. Clinical trials for JADE101, JADE201, and JADE301 are ongoing, with data expected in 2027.

JBIO sentiment & insider activity

Over the past 7 days, AlphAI's AI scored 6 news stories mentioning JBIO (Jade Biosciences, Inc.). Coverage has skewed bearish: 2 bullish, 0 neutral, and 4 bearish.

Recent JBIO coverage spans financial news, earnings and technology.

What's driving JBIO

AlphAI scores every news story that mentions JBIO with an AI model for sentiment and relevance, and aggregates insider trades from Jade Biosciences, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $JBIO

Score

Guggenheim cuts Jade Biosciences stock price target on model changes

Guggenheim reduced its price target for Jade Biosciences (JBIO) to $41 from $47, citing model adjustments. The stock trades at $16.14, below the analyst consensus range of $40-$77. The company expects to start a Phase 3 trial for JADE101 this quarter and report interim Phase 2 data in 2027. Other analysts maintain Buy ratings with higher targets, highlighting the company's clinical progress and financial health.

Jade Biosciences 3Q 2026: EPS ($0.42) — 10-Q Summary

Jade Biosciences reported a wider net loss of $35.06M in Q3 2026, with no revenue and higher operating expenses. Diluted EPS was ($0.42). The company has $475.7M in cash and expects it to last 12 months. Clinical trials for JADE101, JADE201, and JADE301 are ongoing, with data expected in 2027.

$JBIOMedEarnings

Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update

Jade Biosciences, Inc. (JBIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Jade Biosciences Reports Third Quarter 2026 Financial Results and Provides Corporate Update • JADE101 Phase 3 registrational trial in IgA nephropathy (EVERGREEN) expected to initiate in the fourth quarter of 2026 • JADE101 Phase 2 clinical trial in IgA nephropathy (J

MedAI 8/10

BTIG reiterates Buy rating on Jade Biosciences, $77 price target

BTIG reiterated a Buy rating on Jade Biosciences with a $77 price target, implying a 431% upside from the Oct 26 close of $14.50. The target is based on strong clinical data for JADE101, showing a 70% reduction in IgA levels, and rapid clinical trial advancements, including a Phase 3 trial expected in 4Q26.

$JBIOMedAI 8/10Clinical / regulatory· trial start

Jade Biosciences, Inc. announced preclinical data characterizing JADE301, its anti-interferon beta monoclonal antibody in development for dermatomyositis, a…

Jade Biosciences, Inc. (JBIO) filed an SEC Form 8-K — Other Events. Item 8.01. Other Events. On September 30, 2026, Jade Biosciences, Inc. (“Jade”) announced preclinical data characterizing JADE301, its anti-interferon beta (“IFN-ß”) monoclonal antibody in development for dermatomyositis (“DM”), a rare, chronic and debilitating autoimmune disease

Related tickers